Selective expression of lysyl oxidase (LOX) in the stromal reactions of broncho-pulmonary carcinomas

• Peyrol, S. ^[1] ; Galateau-Salle, F. ^[2] ; Raccurt, M. ^[3] ; Gleyzal, C. ^[4] ; Sommer, P. ^[4]
  1. [1] Common Center for Electron Miscrocopy, University Claude Bernard, Lyon, France
  2. [2] Department of Pathology, Hospital-University Center, Caen, France,
  3. [3] University Claude Bernard, Campus La Doua, Lyon , France
  4. [4] Institute of Biology and Chemistry of Proteins, National Center for the Scientific Research (CNRS), Lyon, France

  Mostrar afiliaciones +
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 15, Nº. 4, 2000, págs. 1127-1135
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Lysyl oxidase (LOX) is the extracellular enzyme that initiates the main pathway of collagen and elastin cross-linking. LOX has also been correlated with the ras recision gene, a putative tumour suppressor isolated from revertants of ras-transformed fibroblasts.

    The present study investigates the potential correlation of LOX-dependent matrix protein cross-linking in the stromal reaction of lung carcinomas, with reference to the architecture of the main stromal reactions accompanying the neoplastic breast tissues. A strong LOX expression was associated with the hypertrophic scar-like stromal reaction found at the front of tumour progression in squamous carcinomas, adenocarcinomas, large cell carcinomas, or at sites of initial extense in bronchiolo-alveolar carcinomas. In contrast, little or no LOX expression was found within the stromal reaction of inva ive carcinomas, small cell carcinomas, and neuro-endocrine carcinomas. The significance of LOX expression and of the stromal reaction are discussed, in light of data that associate LOX expression with tumours displaying a rather good prognosis.